GameChangers: Pharmacotherapy Review of Narcolepsy

GameChangers: Pharmacotherapy Review of Narcolepsy

Narcolepsy can exact a devastating toll on the (probably underdiagnosed) patient. Treatment can range from lifestyle to medications. Join host, Geoff Wall, as he explores a new oral orexin agonist for the treatment of narcolepsy.

THE GAMECHANGER: Narcolepsy is more common than assumed. Current treatments include stimulant agents but a new class of orexin agonists may be effective, yet have safety concerns.

Upon successful completion of this course, learners should be able to:
1. Describe the manifestations, prevalence, and types of narcolepsy and associated symptoms.
2. Discuss the benefits and risks of orexin drugs in treatment of narcolepsy.

Geoffrey C. Wall, PharmD, FCCP, BCPS, CG
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences

Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.  

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: August 28, 2023
Planned Expiration Date: August 28, 2024

Copyright 2023, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.  

Universal Activity Number (UAN): 0107-0000-23-292-H01-P
Application-based CPE Activity

CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at

¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.

Additional information


0h 30m

Topic Designator

Disease State/Drug Therapy



ACPE Topic

01 Drug Therapy





Release Date






ACPE Number


This course is in our subscription.